NEW YORK (Reuters) - A federal jury in Chicago on Monday found AbbVie Inc fraudulently misrepresented the risks of its testosterone replacement drug AndroGel and ordered the drugmaker to pay $150 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results